Tashfeen Posted - 1 day ago

@Steve_TheBull_Rogers all MASH plays are depressed. Any interesting flow on $MDGL and $AKRO

Whiskeyunderthebed Posted - 2 days ago

$AKRO does anyone have any clear insight on why this stock is down for over 23 plus days...I understand they have a bunch P2's in the works and the prelim's look quite good. Thanks.

Writeput Posted - 2 days ago

$AKRO does this turn out to be a fraud ?

Okenrav Posted - 3 days ago

$AKRO $ALT $GALT $MDGL $VKTX 🐂💩! All he did was to enable humanity to drink thrice as much before cirrhosis eventually reigns supreme.

All_just_a_game Posted - 3 days ago

$MDGL $ALT $VKTX $GALT $AKRO RIP to a man who helped many lives and advanced humanity….even after his death, with all his contributions to medicine, many will benefit.

hephais Posted - 1 week ago

$AKRO I truly wonder what did they watch from this firm. lol

TheGunnerAB Posted - 1 week ago

$AKRO @RNASequencing LOL

xyz200 Posted - 1 week ago

$AKRO Where are the clowns that touted this in the 30s??? lol. Oh where are you, you kings of investing lol. idiots.......

Writeput Posted - 1 week ago

$AKRO keeps doing sharp turns mid-day.

xyz200 Posted - 1 week ago

$AKRO DEAD stock

BioRich Posted - 2 weeks ago

$AKRO haven't been following but did it have a NASH fail at the end of last year that caused a dump? Any hope for recovery for this one. I had been following because it looked promising.

buffa1949 Posted - 2 weeks ago

$AKRO LPCN Yesterday LPCN news on fat reducing study but lean muscle does not reduce, just fat.

hephais Posted - 2 weeks ago

$AKRO Maybe, 36 weeks was too short. But, I think 96 weeks will be enough for proof the EFX for Cirrhosis. I believe they could show much better results in 2025 1Q

Yousof Posted - 2 weeks ago

$AKRO did they not sell 12 mio shares for 29$? Did these institutions not done their research probably?

Pharmer23 Posted - 2 weeks ago

$AKRO added more on the dip . I can wait all year

StockInvest_us Posted - 2 weeks ago

Signal alert: $AKRO - Oversold Trend Short (Undervalued) https://stockinvest.us/l/NSj2XuoTSH

StockInvest_us Posted - 3 weeks ago

Signal alert: $AKRO - Oversold Trend Short (Undervalued) https://stockinvest.us/l/PCZaCMmniw

Writeput Posted - 3 weeks ago

$AKRO is this going back to teens ?

hephais Posted - 3 weeks ago

$AKRO Insanely Undervalued… In 25 1Q, It will Explode

Justy_Nuff Posted - 3 weeks ago

$AKRO

xyz200 Posted - 3 weeks ago

$AKRO and down and down it goes. wow. this is going to 4 or 5 bucks at this rate.....

NumberWang Posted - 3 weeks ago

bought starters in $MDGL $AKRO $VKTX $REVG and $EQH

tommaso98 Posted - 3 weeks ago

$AKRO let's reopen the market in a good way

Goreburnelli Posted - 03/30/24

@scanningforbiotechstocks whilst i own both stocks, I think the case for $VKTX rests more solely on its obesity use case, not so much on MASH. Reason being that their MASH candidate still is only in Phase 2 (will take another 3 years or so before coming to market), whilst their competition is already in Phase 3. Their biggest competitor isn’t $MDGL, it is guys like $AKRO, $ETNB who will be releasing Phase 3 in 2025. By the time $VKTX MASH candidate comes out in the market, they will have to beat the FGF21 and PPAR drugs (much higher benchmark). $MDGL has already won the MASH race, so they will dominate the market uncontested over the next 3-5 years. Very very good short to mid-term potential. Their financials will be extremely strong (better than what most are projecting) That said, the TAM of obesity is far larger than MASH, so $VKTX does have a far larger upside potential!

Jinnss Posted - 03/30/24

$AKRO 96wk Topline result of F4 trial (SYMMETRY) in 1Q25

NumberWang Posted - 03/30/24

In addition to #watchlist picks, I am going to take small starter positions on $MDGL $AKRO and $VKTX and will be strategically adding on dips. Very interesting space and a nice hefty dose of biotech risk, of course.

valueforme Posted - 03/29/24

$SGMT Tim Walbert joined the Sagimet board of directors not for money. He is doing VERY WELL financially after Horizon M&A - sec.gov/Archives/edgar/data... if interested. Why has he joined? My guess - to structure a big transaction around denifanstat, which is going to happen sooner than later. There is evidence that FASN inhibitors are complimentary to GLP-1 add THRß agonists. And future of MASH is in combo treatments. The valuation gap between SGMT and FGF21 focused $AKRO and $ETNB is way too significant at the moment. SGMT is just 1 year behind on the trials schedule, at the same time EV looks very different (numbers from YCharts): - ENTB ~ 500M - AKRO ~ 1.2B - SGMT ~ 80M Yes, SGMT does not have enough cash to complete phase 3 trials. And this is what Walbert needs to help with - help figure out what to do - partner before phase 3, sell the company, else.

xyz200 Posted - 1 month ago

$AKRO Dead Stock. The decline remains.....

Writeput Posted - 1 month ago

$AKRO is slacking from $VKTX a lot.